Pioneering solutions, saving lives
Research is critical to combatting brain disease and improving the lives of those impacted, today and in the future.
Conducted by The Royal Melbourne Hospital’s Departments of Neurology and Neurosurgery, the active research programs and clinical trials supported by the Foundation cover an extensive breadth of neurological conditions.
Patients wishing to participate are encouraged to view the relevant trial and contact the trial co-ordinator for more information.
| Brain Tumour / Neurosurgery: | NsurgClerk@mh.org.au |
| Dementia: | DementiaTrials@mh.org.au |
| Epilepsy: | EpilepsyCoordinator@mh.org.au |
| Huntington’s Disease: | RMHHuntingtonDiseaseStudies@mh.org.au |
| Movement Disorders: | PDNurse@mh.org.au |
| Multiple Sclerosis: | MSClinic@mh.org.au |
| Neurophysiology: | RMH-ClinicalNeurophysiology@mh.org.au |
| Stroke: | RMH-StrokeResearchTeam@mh.org.au |
| General: | Neuro.Foundation@mh.org.au |
A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults with Refractory Relapsing or Progressing Multiple Sclerosis
A Phase 2, Randomized, Double-blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Spasticity in Participants with Multiple Sclerosis (BALANCE-MSS-1)
A phase III randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab during a relapse, of Myelin Oligodendrocyte Glycoprotein antibody-associated disease
Fatigue in Relapsing Multiple Sclerosis Epstein Barr Virus Treatment Trial – FiRMS EBV
CLOU064C12306: A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib